Amprenavir: a new HIV protease inhibitor.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002219:Carbamates; D002648:Child; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D005076:Exanthema / Q000139:chemically induced; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced; D013449:Sulfonamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir